Papadimitrakopoulou, V. A. (2016). AURA3 trial: Does Tagrisso (osimertinib) have the potential to become the new standard of care for second-line treatment of patients with EGFR T790M mutation-positive locally advanced or metastatic NSCLC. Lung Cancer Manag.
শিকাগো স্টাইলে সাইটেশনPapadimitrakopoulou, Vassiliki A. "AURA3 Trial: Does Tagrisso (osimertinib) Have the Potential to Become the New Standard of Care for Second-line Treatment of Patients With EGFR T790M Mutation-positive Locally Advanced or Metastatic NSCLC." Lung Cancer Manag 2016.
এমএলএ সাইটেশনPapadimitrakopoulou, Vassiliki A. "AURA3 Trial: Does Tagrisso (osimertinib) Have the Potential to Become the New Standard of Care for Second-line Treatment of Patients With EGFR T790M Mutation-positive Locally Advanced or Metastatic NSCLC." Lung Cancer Manag 2016.